Compare YRD & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YRD | CSBR |
|---|---|---|
| Founded | 2012 | 1985 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.5M | 65.4M |
| IPO Year | 2015 | 2015 |
| Metric | YRD | CSBR |
|---|---|---|
| Price | $0.36 | $4.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 6.8K |
| Earning Date | 11-24-2026 | 12-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,900,000.00 |
| Revenue This Year | $425.24 | $9.83 |
| Revenue Next Year | N/A | $8.50 |
| P/E Ratio | $1.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $4.59 |
| 52 Week High | $5.60 | $8.31 |
| Indicator | YRD | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 26.97 | 46.04 |
| Support Level | $0.36 | $4.71 |
| Resistance Level | $1.05 | $5.17 |
| Average True Range (ATR) | 0.05 | 0.21 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 1.10 | 29.84 |
Yiren Digital Ltd is an AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. Its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.